At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
alirocumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Alirocumab in Patients With Acute Myocardial Infarction: A Randomized Controlled Double-Blinded Study
In Brief
A Phase 4 clinical trial evaluating alirocumab and placebo for Myocardial Infarction and Hypercholesterolemia. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Phase IV investigator initiated clinical trial to study the effectiveness of alirocumab, an inhibitor of proprotein convertase subtilisin/kexin (PCSK9), versus placebo added to high-intensity statin (atorvastatin 80 mg) in lowering low density lipoprotein (LDL) cholesterol during non-ST segment elevation myocardial infarction (NSTEMI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyocardial Infarction, Hypercholesterolemia
CountriesUnited States
CollaboratorsRegeneron Pharmaceuticals, Sanofi
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartJan 2017
Primary CompletionAug 2018
Study CompletionAug 2018
TodayJul 2026
First PostedOct 19, 2016
Enrollment StartJan 1, 2017
Primary CompletionAug 1, 2018
Study CompletionAug 16, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.7 years ago
Interventions
alirocumabdrug
placebodrug